A Phase I Open-label Study for Subjects With Advanced Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
Advanced Solid Malignancies
Interventions
BIOLOGICAL

PT01 (Pegtomarginase)

PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.

Trial Locations (3)

32224

RECRUITING

Mayo Clinic, Jacksonville

55905

RECRUITING

Mayo Clinic, Rochester

85054

RECRUITING

Mayo Clinic, Phoenix

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Athenex, Inc.

INDUSTRY

NCT04136834 - A Phase I Open-label Study for Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter